Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease. Innate and adaptive immunity cooperatively contribute to the development of SLE. Antigen-presenting cells (APCs) have been suggested to link innate and adaptive immunity. T-cell immunoglobulin-and mucin-domain-containing molecule-4 (Tim-4; also known as Timd4), expressed primarily on the surface of APCs, is a member of the TIM family, a recently described group of molecules that have received much attention as potential regulators of the immune system. In this study, we used quantitative real-time reverse transcription-polymerase chain reaction to examine the mRNA expression of Tim-4 in peripheral blood mononuclear cells (PBMCs) from SLE patients and further analyzed the correlation between the expression of Tim-4 and Tim-1 (a potential ligand for Tim-4) in PBMCs and serum tumor necrosis factor (TNF)-a levels. The results showed that Tim-4 mRNA expression in PBMCs was significantly higher in SLE patients than in healthy controls, especially those patients in the active phase of disease. Moreover, Tim-4 mRNA levels were closely correlated with Tim-1 mRNA levels in PBMCs and with serum TNF-a levels in SLE patients but not in the control group. Taken together, these results demonstrate that Tim-4 may be involved in the pathogenesis of SLE.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a typical inflammatory autoimmune disease with a broad spectrum of clinical and immunological abnormalities. 1 It occurs worldwide at an increased frequency every year and is particularly common in people of Asian origin. 2 In China, SLE is a major public health problem with a prevalence of 31 to 70 cases per 100 000 people. 3, 4 This disease has a huge impact on quality of life due to side effects of the currently available therapies and a significantly increased risk of developing cardiovascular diseases, certain types of cancer and many other kinds of diseases. [5] [6] [7] [8] [9] However, the precise etiology of SLE remains unclear. Over the past several decades, SLE has been described as a complex immune disorder, characterized by abnormal B-and T-cell reactivities, loss of tolerance to nucleic acid antigens and production of the corresponding autoantibodies. 10, 11 Recently, accumulating evidence has shown that innate immunity also plays a role in the initiation and perpetuation of SLE. [12] [13] [14] Increased levels of inflammatory factors, such as IL-17 and tumor necrosis factor (TNF)-a, are detected in the serum from patients with SLE. [15] [16] [17] [18] [19] Macrophages, a major cellular constituent of innate immunity and an effective antigen presenting cell (APC) for bridging innate and adaptive immunity, have been widely linked to lupus development. Existing studies focus mainly on defects in macrophage or dendritic cell (DC) phagocytosis, resulting in accumulation of apoptotic debris leading to an array of autoimmune phenomena. Additional data have revealed the diverse changes that occur in monocytes/macrophages and DCs during SLE development, including multiple aberrations in activation status and secretary function. 20, 21 T-cell immunoglobulin-and mucin-domain-containing molecule-1 (Tim-1), which is dominantly expressed in T helper 2 (Th2) cells and involved in the negative regulation of Th2 responses, is a ligand for Tim-4 (also known as Timd4). Interestingly, Tim-4 is not expressed in T cells, but is exclusively expressed in APCs, particularly in mature myeloid-derived DCs and macrophages. 22 Tim-4 can promote T-cell expansion and survival by cross-linking Tim-1 on T cells as a costimulatory molecule. 23 Since Tim-1 has been shown to be a human susceptibility gene for asthma, allergy and autoimmunity and plays an important role during the development of autoimmune diseases, 24 it is reasonable to speculate that Tim-4 may be involved in the maintenance of tissue homeostasis and prevention of autoimmunity. The function of Tim-4 in food allergy and the association of a Tim-4 polymorphism with asthma have been validated, 25, 26 but, it is unclear at present whether Tim-4 is involved in the development of SLE. To clarify the role of Tim-4 in SLE, we examined Tim-4 mRNA expression levels in peripheral blood mononuclear cells (PBMCs) from SLE patients and healthy controls and further evaluated the relationship between Tim-4, Tim-1 and TNF-a.
MATERIALS AND METHODS
Patients and blood samples All samples were collected from Qilu Hospital, Shandong University. Sera were collected from a total of 25 patients, each fulfilling the American College of Rheumatology classification criteria for SLE. 27, 28 Sera were also collected from 24 healthy controls at the Shandong Blood Center, and all recruited healthy controls were excluded from having any autoimmune diseases. There were no significant differences in the ages or sex ratios between the two groups. For SLE patients, no subjects received any immune-modulatory treatment during the 1-month period before sampling. This study was approved by the Medical Ethics Committee of Shandong University, and informed consent was obtained from all of the subjects before the study. The characteristics of the SLE patients and healthy controls are summarized in Table 1 .
PBMC isolation and quantitative real-time reverse transcription polymerase chain reaction (real-time RT-PCR) Blood samples were collected from patients and healthy donors in sterile containers with Natrium Citricum. PBMCs were then isolated by Ficoll density-gradient centrifugation. Cells from the interface were collected and washed twice with Dulbecco's phosphate-buffered saline. Cell pellets were lysed with TRIZOL reagent (Invitrogen, Shanghai, China) at a ratio of 1 ml TRIZOL per 10 7 cells. Total RNA from PBMCs was extracted following the manufacturer's instructions. One microgram of total RNA was used for cDNA synthesis with an oligo (dT) primer and Moloney murine leukemia virus reverse transcriptase (Promega, Jinan, China). Specific primers were designed based on the human Tim-4 and Tim-1 gene sequences (GeneID no. 91937 and no. 26762 separately). Specific primers used for real-time RT-PCR were 59-ACAGGACAGATGGATGGAATACCC-39 (forward) and 59-AGCCTTGTGTGTTTCTG CG-39 (reverse) for Tim-4 and 59-CCAGTAGCCACTTCACCATCTTCAC-39 (forward) and 59-CGGTGTCATTCCCATCTGTTGTG-39 (reverse) for Tim-1.
The following primers for human b-actin were included as an internal control: 59-AGTTGCGTTACACCCTTTC-39 (forward) and 59-CCTTCACCGTTCCAGTTT-39 (reverse).
The final volume of real-time RT-PCR reaction was 20 ml, containing 1 mg of total RNA, 1 ml of oligo (dT)n, 2 ml of 10 nmol/l dNTP and 1 ml of Moloney murine leukemia virus reverse transcriptase (200 U; Promega). The amplification was performed using an ABI PRISM 7000 Sequence Detection System (Perkin-Elmer, Norwalk, CT, USA) with a two-step PCR protocol (95 uC for 10 min, followed by 40 cycles of 95 uC for 15 s and 60 uC for 1 min). Each sample was run in triplicate.
ELISA for TNF-a Serum was separated in the usual manner and prepared for TNF-a analysis. TNF-a levels in the serum from SLE patients and healthy controls were measured using an ELISA kit (Jingmei Bio-medical Corporation, Shanghai, China) according to the manufacturer's instructions. Briefly, serum samples were applied to the 96-well ELISA microplate precoated with capture antibody. The capture antibody-bound cytokines were detected with biotin-conjugated anti-TNF-a antibody and horseradish peroxidase (HRP)-conjugated Avidin. Two duplicate wells were prepared for each sample. Absorbance was measured using a microplate reader (Bio-Rad, Beijing, China) at a wavelength of 450 nm. Concentrations of TNFa were determined by a standard curve according to the manufacturer's instructions. The intra-and inter-assay coefficients of variations (CV) were all ,10%.
Statistical analysis
Differences in relative Tim-4 mRNA expression and TNF-a levels between SLE patients and healthy controls were determined by a two-tailed non-parametric test (Mann Whitney test, GraphPad Prism 5.0, GraphPad Software Inc., San Diego, CA, USA). Correlations between Tim-4 mRNA and Tim-1 mRNA or TNF-a levels in SLE patients were analyzed with Spearman's rank test (GraphPad Prism 5.0). A P value below 0.05 was considered statistically significant.
RESULTS
Increased expression of Tim-4 in PBMCs from SLE patients, especially those in an active phase of disease We examined Tim-4 mRNA expression levels in PBMCs from SLE patients and healthy controls by real-time RT-PCR for the first time. As shown in Figure 1a , expression levels of Tim-4 mRNA were significantly higher in SLE patients (median 0.3108, interquartile range (IQR) 0.1690-1.323) than in healthy subjects (median 0.1460, IQR 0.08677-0.2753) (P50.002). We further grouped the SLE patients by active or inactive phase according to their Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores. 29 The results showed that Tim-4 mRNA levels in SLE patients with active disease (median 1.495, IQR 0.9768-2.366) were significantly higher than those with inactive disease (median 0.2378, IQR 0.1525-0.4299) (P50.0056) (Figure 1b) , suggesting that Tim-4 expression is related to SLE disease activity.
Positive correlation between Tim-4 and Tim-1 mRNA expression levels in PBMCs from SLE patients We also examined the mRNA expression levels of Tim-1, a receptor of Tim-4 that was discovered in 2005. The results showed that there was no significant difference in Tim-1 mRNA levels in PBMCs between SLE patients and healthy controls (data not shown). We did find, 
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however, that Tim-1 mRNA levels positively correlated with Tim-4 levels in PBMCs from SLE patients (P,0.01, r50.6112) (Figure 2a ), but not in healthy controls (P.0.05, r50.255) (Figure 2b ), suggesting that the interaction of Tim-1 and Tim-4 may be involved in the pathogenesis of SLE.
Positive correlation of Tim-4 mRNA in PBMCs with serum TNF-a concentration in SLE patients
We measured serum TNF-a concentrations in SLE patients and healthy controls by ELISA. The results showed that the mean TNF-a level in SLE patients (median 71.73 pg/ml, IQR 56.11-82.15 pg/ml) was significantly higher than the level in healthy subjects (median 20.83, IQR 11.86-29.79 pg/ml) (P,0.0001) (Figure 3a) . These results indicate that TNF-a plays an important role in the development of SLE, which is consistent with data from other labs. 16, 17 We also found a positive correlation between Tim-4 mRNA levels in PBMCs and TNF-a concentrations in serum in SLE patients (P,0.05, r50.4204) (Figure 3b ).
DISCUSSION
TIM was first discovered in 2001 as a new gene family related to asthma and allergic diseases in mice. 30 The TIM gene family includes three members (Tim-1, Tim-3 and Tim-4) in humans and eight members (Tim-1 to Tim-8) in mice. 31 Due to its unique structure, the TIM gene family is thought to participate in the regulation of immunological processes. Tim-1 and Tim-2 are found in Th2 cells and involved in the negative regulation of Th2 responses, while Tim-3 is preferentially expressed in Th1 cells and suppresses Th1 responses. Tim-3 has been proposed to be a novel candidate target for the treatment of SLE. [32] [33] [34] [35] [36] [37] Unlike the other Tim molecules, Tim-4 is exclusively expressed in APCs and it is unclear to date whether Tim-4 plays a role in SLE pathogenesis. Due to the lack of a directly labeled anti-human Tim-4 antibody, it is difficult to quantitate Tim-4 protein on APCs by flow cytometry. Since Tim-4 is preferentially expressed on APCs, its expression on PBMCs can be used to monitor the expression on APCs. Thus, in this study, we examine Tim-4 mRNA expression in PBMCs by real-time RT-PCR. We firstly demonstrate that Tim-4 mRNA expression in PBMCs from patients with SLE is higher than those from healthy controls. Moreover, Tim-4 mRNA levels in SLE patients during an active phase of disease are significantly higher than the levels in patients at an inactive phase, which are also significantly higher than those of healthy controls (data not shown). Our primary result implies that Tim-4 mRNA expression increases during the development of SLE, when monocytes or DCs are activated by immune complexes or autoantibodies. 38, 39 This result is consistent with our finding that Tim-4 expression increases in RAW264.7 cells stimulated by lipopo- Figure 1 Tim-4 mRNA expression levels in PBMCs from SLE patients and healthy controls. Tim-4 mRNA expression levels in PBMCs were determined by real-time RT-PCR. The results show that the mean expression levels of Tim-4 mRNA in PBMCs from SLE patients were significantly higher than those in healthy controls (a). We divided the SLE patients into two groups: active phase (SLEDAI.10) or inactive phase (SLEDAI,5) and found that Tim-4 mRNA levels were significantly higher in patients in the active phase than in those in the inactive phase (b). Each point represents an individual patient and medians are marked for each group. PBMCs, peripheral blood mononuclear cells; RT-PCR, reverse transcription polymerase chain reaction; SLE, systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; Tim-4, T-cell immunoglobulin-and mucin-domain-containing molecule-4. Studies show that Tim-4 is the natural ligand for Tim-1. 22 In a previous report, increased levels of Tim-1 were detected in SLE patients, which correlated with IL-10 expression. 40 However, we failed to detect any significant difference in Tim-1 mRNA levels in PBMCs from SLE patients versus healthy controls. This discrepancy may be due to differences in the SLEDAI of patients involved in each study: in the previous report, 17 out of 19 SLE patients had a SLEDAI higher than 5, while in the present study most patients (19/25) had a SLEDAI lower than 5. The interaction between Tim-1 and Tim-4 is involved in modulation of T-cell proliferation, but the effect of Tim-4 on T-cell activation and proliferation is bimodal and depends on the activation status of the T cells. In naive T cells, Tim-4 negatively regulates activation via a ligand other than Tim-1, while Tim-4 positively regulates activation through Tim-1 in pre-activated T cells. 41 Emerging reports show that DCderived Tim-4 plays an important role in the initiation of peanut extract-specific Th2 polarization and allergy in the intestine, 42 which may explain our result that Tim-4 is positively correlated with Tim-1 in SLE patients but not in healthy controls. In SLE patients, cells overexpressing Tim-4 might bind to pre-activated Tim-1-bearing T cells, especially Th2 cells, and promote Th2-mediated immune responses, consistent with the idea that SLE is Th2-polarized autoimmune disease.
The expression of many kinds of inflammatory factors is upregulated in SLE patients. [15] [16] [17] [18] [19] Consistent with data from other labs, we report here that SLE patients have increased serum TNF-a levels. [43] [44] [45] TNF-a, a common marker for the activation status of macrophages and DCs, is primarily secreted by activated monocytes/macrophages and may induce the increased expression of Tim-4, thus promoting Th2 cell proliferation via interaction with Tim-1. Although we did not measure other cytokines in SLE patients, our unpublished data from macrophage cell lines demonstrates that Tim-4 expression correlates well with other proinflammatory cytokines such as IL-1b and IL-6. Thus, we propose that Tim-4 is an important immune regulator in SLE. Moreover, Tim-4 is a receptor for phosphatidylserine 46 and may induce macrophages and DCs to engulf more cell corpses to maintain the immune balance, particularly given the increased apoptotic load in SLE patients with active disease.
In conclusion, we are the first to demonstrate the difference in Tim-4 expression in PBMCs between SLE patients and healthy controls. Although the sample size in this study is small, Tim-4 mRNA expression in PBMCs positively correlates with Tim-1 and TNF-a levels in SLE patients but not in healthy controls, which suggests that Tim-4, at least in part, plays a role in the aggravation of SLE. The function of Tim-4 and its role in the pathogenesis of SLE warrant further investigation. Figure 3 Serum TNF-a levels and positive correlation with Tim-4 mRNA expression levels in PBMCs from SLE patients. TNF-a levels in serum were determined by ELISA. The concentrations of TNF-a in SLE patients were significantly higher than those in healthy controls (a). There was a positive correlation between serum TNF-a concentrations and Tim-4 mRNA levels in PBMCs from SLE patients (b). Each point represents an individual patient and the median for each group is shown. PBMCs, peripheral blood mononuclear cells; SLE, systemic lupus erythematosus; Tim-4, T-cell immunoglobulin-and mucin-domain-containing molecule-4; TNF, tumor necrosis factor.
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